Lung cancer’s speed of spread depends heavily on the type. Small cell lung cancer doubles in size roughly every 73 days, making it the fastest-growing form. The most common type, adenocarcinoma, doubles about every 223 days, while squamous cell carcinoma falls in between at around 140 days. These are averages from pooled imaging studies, and individual tumors can behave very differently depending on their genetic makeup, location, and how early they’re caught.
Growth Speed by Tumor Type
Lung cancer isn’t one disease. The two broad categories, non-small cell (NSCLC) and small cell (SCLC), behave differently at almost every level, and growth rate is one of the starkest differences.
Small cell lung cancer is the most aggressive. With a volume doubling time of about 73 days, a tumor can grow substantially in just a few months. SCLC also tends to metastasize early. By the time it’s diagnosed, it has often already spread beyond the lung. Doctors classify it as either “limited stage,” meaning it’s still on one side of the chest, or “extensive stage,” meaning it has reached the other lung, distant organs, or the fluid surrounding the lungs or heart. Most people are diagnosed at the extensive stage.
Non-small cell lung cancer accounts for roughly 80 to 85 percent of cases, and its subtypes grow at different rates. Adenocarcinoma, the most common subtype, has a doubling time of about 223 days. That’s roughly seven and a half months for the tumor to double in volume. Squamous cell carcinoma grows faster, doubling in about 140 days. Other rarer subtypes average around 178 days. These differences matter because a faster doubling time generally means a narrower window between a screenable, treatable tumor and one that has already spread.
How Genetics Influence Spread
Two tumors of the same type can behave very differently depending on the genetic mutations driving them. In lung adenocarcinoma, two of the most studied mutations involve genes called EGFR and KRAS. Both promote cell division and help cancer cells invade surrounding tissue, but KRAS mutations are linked to notably more aggressive behavior.
Patients with KRAS-mutated tumors tend to have larger tumors at diagnosis, higher cancer staging, and worse survival compared to those with EGFR mutations. One telling measure: secondary lung nodules (new spots that develop after the primary tumor is treated) progress to a threatening, invasive size about 27 months faster in KRAS-mutated cancers than in EGFR-mutated ones. That difference, roughly 40 months versus 68 months of progression-free time, is significant enough that closer post-surgery monitoring with CT scans is recommended for KRAS patients.
Where Lung Cancer Spreads First
When lung cancer metastasizes, it tends to follow predictable routes. The most common destinations are the brain and nervous system, bones, liver, the other lung, and the adrenal glands (small glands sitting on top of your kidneys).
The pattern differs by cancer type. Small cell lung cancer most often spreads to the brain and nervous system (47% of metastatic cases) and liver (35%). Adenocarcinoma favors bone (39%) and other parts of the respiratory system (22%). Women and younger patients are more likely to develop brain metastases than older men.
Symptoms That Signal Spread
Many people with early-stage lung cancer have no symptoms at all, which is part of why it’s so often caught late. When the cancer does spread to distant organs, the symptoms depend on where it lands.
If lung cancer reaches the brain, it can cause persistent headaches (often with nausea), memory problems, personality or mood changes, confusion, seizures, or weakness in an arm or leg. These symptoms can develop gradually or appear suddenly.
Bone metastases cause pain, most commonly in the lower back when cancer settles in the spine. Bones become weaker and may fracture more easily. Calcium can leak from damaged bones into the bloodstream, leading to dehydration and confusion. In some cases, tumors in the spinal bones press on the spinal cord itself, causing leg weakness, numbness, or loss of bladder and bowel control. This is a medical emergency.
Liver metastases often show up as discomfort or pain on the right side of your abdomen, nausea, poor appetite, weight loss, a swollen belly from fluid buildup, yellowing of the skin, or itching.
How Staging Affects Survival
The speed of spread matters most in practical terms because of how dramatically it changes the prognosis. Data from the U.S. National Cancer Institute’s SEER program (covering 2016 to 2022) lays this out clearly with five-year survival rates by stage at diagnosis:
- Localized (still confined to the lung): 65.5%
- Regional (spread to nearby lymph nodes): 38.2%
- Distant (metastasized to other organs): 10.5%
That gap between localized and distant, from roughly two in three people surviving five years down to one in ten, is one of the largest stage-dependent differences in any common cancer. It’s the core reason lung cancer screening with low-dose CT scans exists for high-risk individuals. Catching a tumor while it’s still localized changes the math entirely.
The Limits of Detecting Spread
One challenge with tracking how fast lung cancer spreads is that small metastases can be invisible on standard imaging. PET scans, which detect cancer by measuring metabolic activity, are highly accurate for nodules larger than 5 mm, picking up about 95% of metastatic spots at that size. But for nodules smaller than 5 mm, sensitivity drops to just 13%. That means very early metastatic deposits can exist without showing up on a scan, which is partly why cancers sometimes seem to “suddenly” appear in distant organs after a clean scan months earlier. CT scans can detect smaller nodules structurally, but distinguishing a tiny metastasis from a harmless spot remains difficult below that 5 mm threshold.
Does Smoking Speed Up an Existing Tumor?
Smoking is the single biggest risk factor for developing lung cancer, but its role in accelerating a tumor that already exists is less clear-cut than you might expect. Studies looking at whether active smokers’ tumors progress faster or spread in different patterns than former smokers’ tumors have found no significant differences in how the cancer behaves radiologically once it’s established. The damage smoking does is primarily in initiating and promoting cancer development. Once a tumor has formed and acquired its own genetic drivers, its growth trajectory appears to be governed more by those mutations and its cell type than by ongoing tobacco exposure.
That said, continuing to smoke after a lung cancer diagnosis worsens outcomes for other reasons: it reduces lung function, impairs healing after surgery, and can interfere with how well treatments work.